tetano
Editor, Senior Moderator
Virol J
. 2024 Sep 30;21(1):239.
doi: 10.1186/s12985-024-02475-y. Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19
Miloš Bohoněk[SUP] 1 2 [/SUP], Jan Máca[SUP] 3 4 [/SUP], Jiří Sagan[SUP] 5 6 [/SUP], David Řezáč[SUP] 7 [/SUP], Viktor Fridrich[SUP] 8 [/SUP], Anna Burantová[SUP] 8 [/SUP], Dominik Kutáč[SUP] 1 [/SUP], Pavel Vabroušek[SUP] 1 [/SUP], Jan Kubů[SUP] 9 [/SUP], Aleš Chrdle[SUP] 10 11 [/SUP], Kateřina Volfová[SUP] 10 [/SUP], Šárka Blahutová[SUP] 12 [/SUP], Ivan Rychlík[SUP] 13 [/SUP], Kateřina Vonášková[SUP] 13 [/SUP], Radek Majerčin[SUP] 14 [/SUP], Radka Králová[SUP] 14 [/SUP], Petr Štěpánek[SUP] 15 [/SUP], Michal Holub[SUP] 16 17 [/SUP]
Affiliations
Purpose: Convalescent plasma (CP) collected from people who recovered from COVID-19 became a rapidly available treatment modality in numerous countries, including the Czech Republic. The aims of our study were to evaluate the effectiveness and safety of CP in the treatment of COVID-19.
Methods: This retrospective observational study involved six Czech hospitals. This study enrolled patients with and without CP treatment who were hospitalized between April 2020 and April 2021. Propensity score matching and logistic regression analysis were performed to evaluate the influence of CP administration and its timing on the in-hospital survival of COVID-19 patients.
Results: A total of 1,498 patients were enrolled in the study; 406 (27%) were administered CP, and 1,092 (73%) were not treated with CP. The propensity score-matched control group consisted of 1,218 subjects. The survival of patients treated with CP was 79%, while that of patients in the matched control group was 62% (P<0.001). Moreover, the chance of survival was significantly greater when CP was administered within three days after the onset of COVID-19 symptoms than when CP was administered after four or more days (87% vs. 76%, P <0.001). In addition, adverse effects related to CP administration were recorded in only 2% of patients and were considered mild in all patients.
Conclusions: Our study demonstrated that the administration of CP was safe and possibly associated with positive effects that were more pronounced if CP was administered within the first three days after the onset of COVID-19 symptoms.
Keywords: COVID-19; Convalescent plasma; Outcome; SARS-CoV-2.
. 2024 Sep 30;21(1):239.
doi: 10.1186/s12985-024-02475-y. Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19
Miloš Bohoněk[SUP] 1 2 [/SUP], Jan Máca[SUP] 3 4 [/SUP], Jiří Sagan[SUP] 5 6 [/SUP], David Řezáč[SUP] 7 [/SUP], Viktor Fridrich[SUP] 8 [/SUP], Anna Burantová[SUP] 8 [/SUP], Dominik Kutáč[SUP] 1 [/SUP], Pavel Vabroušek[SUP] 1 [/SUP], Jan Kubů[SUP] 9 [/SUP], Aleš Chrdle[SUP] 10 11 [/SUP], Kateřina Volfová[SUP] 10 [/SUP], Šárka Blahutová[SUP] 12 [/SUP], Ivan Rychlík[SUP] 13 [/SUP], Kateřina Vonášková[SUP] 13 [/SUP], Radek Majerčin[SUP] 14 [/SUP], Radka Králová[SUP] 14 [/SUP], Petr Štěpánek[SUP] 15 [/SUP], Michal Holub[SUP] 16 17 [/SUP]
Affiliations
- PMID: 39350163
- PMCID: PMC11443855
- DOI: 10.1186/s12985-024-02475-y
Purpose: Convalescent plasma (CP) collected from people who recovered from COVID-19 became a rapidly available treatment modality in numerous countries, including the Czech Republic. The aims of our study were to evaluate the effectiveness and safety of CP in the treatment of COVID-19.
Methods: This retrospective observational study involved six Czech hospitals. This study enrolled patients with and without CP treatment who were hospitalized between April 2020 and April 2021. Propensity score matching and logistic regression analysis were performed to evaluate the influence of CP administration and its timing on the in-hospital survival of COVID-19 patients.
Results: A total of 1,498 patients were enrolled in the study; 406 (27%) were administered CP, and 1,092 (73%) were not treated with CP. The propensity score-matched control group consisted of 1,218 subjects. The survival of patients treated with CP was 79%, while that of patients in the matched control group was 62% (P<0.001). Moreover, the chance of survival was significantly greater when CP was administered within three days after the onset of COVID-19 symptoms than when CP was administered after four or more days (87% vs. 76%, P <0.001). In addition, adverse effects related to CP administration were recorded in only 2% of patients and were considered mild in all patients.
Conclusions: Our study demonstrated that the administration of CP was safe and possibly associated with positive effects that were more pronounced if CP was administered within the first three days after the onset of COVID-19 symptoms.
Keywords: COVID-19; Convalescent plasma; Outcome; SARS-CoV-2.